Literature DB >> 27890865

CSF-PR 2.0: An Interactive Literature Guide to Quantitative Cerebrospinal Fluid Mass Spectrometry Data from Neurodegenerative Disorders.

Astrid Guldbrandsen1,2, Yehia Farag1,2, Ann Cathrine Kroksveen1,2, Eystein Oveland1,2, Ragnhild R Lereim1,2, Jill A Opsahl1,2, Kjell-Morten Myhr2,3, Frode S Berven4,2,5, Harald Barsnes1,6,7.   

Abstract

The rapidly growing number of biomedical studies supported by mass spectrometry based quantitative proteomics data has made it increasingly difficult to obtain an overview of the current status of the research field. A better way of organizing the biomedical proteomics information from these studies and making it available to the research community is therefore called for. In the presented work, we have investigated scientific publications describing the analysis of the cerebrospinal fluid proteome in relation to multiple sclerosis, Parkinson's disease and Alzheimer's disease. Based on a detailed set of filtering criteria we extracted 85 data sets containing quantitative information for close to 2000 proteins. This information was made available in CSF-PR 2.0 (http://probe.uib.no/csf-pr-2.0), which includes novel approaches for filtering, visualizing and comparing quantitative proteomics information in an interactive and user-friendly environment. CSF-PR 2.0 will be an invaluable resource for anyone interested in quantitative proteomics on cerebrospinal fluid.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27890865      PMCID: PMC5294216          DOI: 10.1074/mcp.O116.064477

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  55 in total

Review 1.  Ten years of proteomics in multiple sclerosis.

Authors:  Alessandro S Farias; Fernando Pradella; Andrea Schmitt; Leonilda M B Santos; Daniel Martins-de-Souza
Journal:  Proteomics       Date:  2014-03       Impact factor: 3.984

2.  Distributed and interactive visual analysis of omics data.

Authors:  Yehia Farag; Frode S Berven; Inge Jonassen; Kjell Petersen; Harald Barsnes
Journal:  J Proteomics       Date:  2015-06-03       Impact factor: 4.044

3.  Quantitative proteomics and metabolomics analysis of normal human cerebrospinal fluid samples.

Authors:  Marcel P Stoop; Leon Coulier; Therese Rosenling; Shanna Shi; Agnieszka M Smolinska; Lutgarde Buydens; Kirsten Ampt; Christoph Stingl; Adrie Dane; Bas Muilwijk; Ronald L Luitwieler; Peter A E Sillevis Smitt; Rogier Q Hintzen; Rainer Bischoff; Sybren S Wijmenga; Thomas Hankemeier; Alain J van Gool; Theo M Luider
Journal:  Mol Cell Proteomics       Date:  2010-09       Impact factor: 5.911

Review 4.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

5.  Cerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation.

Authors:  Min Shi; James Movius; Romel Dator; Patrick Aro; Yanchun Zhao; Catherine Pan; Xiangmin Lin; Theo K Bammler; Tessandra Stewart; Cyrus P Zabetian; Elaine R Peskind; Shu-Ching Hu; Joseph F Quinn; Douglas R Galasko; Jing Zhang
Journal:  Mol Cell Proteomics       Date:  2015-01-02       Impact factor: 5.911

6.  Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis.

Authors:  S Modvig; M Degn; H Roed; T L Sørensen; H B W Larsson; A R Langkilde; J L Frederiksen; F Sellebjerg
Journal:  Mult Scler       Date:  2015-02-19       Impact factor: 6.312

7.  iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia.

Authors:  Stefan Lehnert; Sarah Jesse; Wolfgang Rist; Petra Steinacker; Hilkka Soininen; Sanna-Kaisa Herukka; Hayrettin Tumani; Martin Lenter; Patrick Oeckl; Boris Ferger; Bastian Hengerer; Markus Otto
Journal:  Exp Neurol       Date:  2012-02-01       Impact factor: 5.330

Review 8.  Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics.

Authors:  Yahui Liu; Hong Qing; Yulin Deng
Journal:  Int J Mol Sci       Date:  2014-05-06       Impact factor: 5.923

9.  A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking.

Authors:  C E Teunissen; A Petzold; J L Bennett; F S Berven; L Brundin; M Comabella; D Franciotta; J L Frederiksen; J O Fleming; R Furlan; R Q Hintzen; S G Hughes; M H Johnson; E Krasulova; J Kuhle; M C Magnone; C Rajda; K Rejdak; H K Schmidt; V van Pesch; E Waubant; C Wolf; G Giovannoni; B Hemmer; H Tumani; F Deisenhammer
Journal:  Neurology       Date:  2009-12-01       Impact factor: 9.910

10.  Gray matter is targeted in first-attack multiple sclerosis.

Authors:  Steven E Schutzer; Thomas E Angel; Tao Liu; Athena A Schepmoes; Fang Xie; Jonas Bergquist; László Vécsei; Denes Zadori; David G Camp; Bart K Holland; Richard D Smith; Patricia K Coyle
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

View more
  10 in total

1.  Signatures of glial activity can be detected in the CSF proteome.

Authors:  Timo Eninger; Stephan A Müller; Mehtap Bacioglu; Manuel Schweighauser; Marius Lambert; Luis F Maia; Jonas J Neher; Sarah M Hornfeck; Ulrike Obermüller; Gernot Kleinberger; Christian Haass; Philipp J Kahle; Matthias Staufenbiel; Lingyan Ping; Duc M Duong; Allan I Levey; Nicholas T Seyfried; Stefan F Lichtenthaler; Mathias Jucker; Stephan A Kaeser
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-06       Impact factor: 12.779

2.  Development of robust targeted proteomics assays for cerebrospinal fluid biomarkers in multiple sclerosis.

Authors:  Astrid Guldbrandsen; Ragnhild Reehorst Lereim; Mari Jacobsen; Hilde Garberg; Ann Cathrine Kroksveen; Harald Barsnes; Frode S Berven
Journal:  Clin Proteomics       Date:  2020-09-18       Impact factor: 3.988

3.  Orthologous proteins of experimental de- and remyelination are differentially regulated in the CSF proteome of multiple sclerosis subtypes.

Authors:  Nellie A Martin; Arkadiusz Nawrocki; Viktor Molnar; Maria L Elkjaer; Eva K Thygesen; Miklos Palkovits; Peter Acs; Tobias Sejbaek; Helle H Nielsen; Zoltan Hegedus; Finn Sellebjerg; Tihamer Molnar; Eudes G V Barbosa; Nicolas Alcaraz; Ferenc Gallyas; Asa F Svenningsen; Jan Baumbach; Hans Lassmann; Martin R Larsen; Zsolt Illes
Journal:  PLoS One       Date:  2018-08-16       Impact factor: 3.240

4.  Multi-Omics Interdisciplinary Research Integration to Accelerate Dementia Biomarker Development (MIRIADE).

Authors:  Ekaterina Mavrina; Leighann Kimble; Katharina Waury; Dea Gogishvili; Nerea Gómez de San José; Shreyasee Das; Salomé Coppens; Bárbara Fernandes Gomes; Sára Mravinacová; Anna Lidia Wojdała; Katharina Bolsewig; Sherif Bayoumy; Felicia Burtscher; Pablo Mohaupt; Eline Willemse; Charlotte Teunissen
Journal:  Front Neurol       Date:  2022-07-12       Impact factor: 4.086

5.  Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer's Disease: ELISA Development and Clinical Validation.

Authors:  Anna Lidia Wojdała; Davide Chiasserini; Giovanni Bellomo; Silvia Paciotti; Lorenzo Gaetani; Federico Paolini Paoletti; Lucilla Parnetti
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

Review 6.  Proteomic Approaches for the Discovery of Biofluid Biomarkers of Neurodegenerative Dementias.

Authors:  Becky C Carlyle; Bianca A Trombetta; Steven E Arnold
Journal:  Proteomes       Date:  2018-08-31

7.  Phosphotyrosine profiling of human cerebrospinal fluid.

Authors:  Gajanan Sathe; Chan Hyun Na; Santosh Renuse; Anil Madugundu; Marilyn Albert; Abhay Moghekar; Akhilesh Pandey
Journal:  Clin Proteomics       Date:  2018-09-12       Impact factor: 3.988

8.  Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease.

Authors:  Jakob M Bader; Philipp E Geyer; Johannes B Müller; Maximilian T Strauss; Manja Koch; Frank Leypoldt; Peter Koertvelyessy; Daniel Bittner; Carola G Schipke; Enise I Incesoy; Oliver Peters; Nikolaus Deigendesch; Mikael Simons; Majken K Jensen; Henrik Zetterberg; Matthias Mann
Journal:  Mol Syst Biol       Date:  2020-06       Impact factor: 11.429

Review 9.  The Implementation of Mass Spectrometry-Based Proteomics Workflows in Clinical Routines of Acute Myeloid Leukemia: Applicability and Perspectives.

Authors:  Maria Hernandez-Valladares; Øystein Bruserud; Frode Selheim
Journal:  Int J Mol Sci       Date:  2020-09-17       Impact factor: 5.923

Review 10.  Proteomic Approaches to Study Cysteine Oxidation: Applications in Neurodegenerative Diseases.

Authors:  Trong Khoa Pham; Weronika A Buczek; Richard J Mead; Pamela J Shaw; Mark O Collins
Journal:  Front Mol Neurosci       Date:  2021-06-09       Impact factor: 5.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.